CT Colonography Software Helps Track Small Polyp Growth and Regression

(Stony Brook, NY, USA) reported that its CTC software, V3D-Colon, was used in the significant clinical study relating to colorectal cancer screening. The latest CTC study, published online June 7, 2013, in the journal Lancet Oncology, tracked polyp growth in 243 patients over an eight-year period.

There is now direct evidence and statistical validation that colorectal polyp-volume growth over time delivers true clinical value for identifying advanced adenomas. The advanced adenoma polyp is the primary target in colorectal cancer screening. When an advanced adenoma polyp is identified and removed, the probability of colorectal cancer developing is significantly reduced.

“Viatronix is extremely proud to have been an integral part of such an important trial,” said Zaffar Hayat, president and CEO of Viatronix. “The Viatronix platform has been the software of choice in several landmark clinical trials over the past10 years. V3D-Colon’s user-friendly interface, diagnostic tools and short read times backed by strong clinical validation make it the system of choice for leading experts.”

This study found further evidence that CTC is effective for colon cancer screening. Screening CTC is currently reimbursed by many insurance carriers and coverage is mandated in approximately 30 States. Presently there is legislation in the US Congress for CMS/Medicare to cover the cost for this invaluable colorectal cancer-screening exam.

Viatronix is a developer of noninvasive 2D/3D medical imaging and diagnostic software that enables physicians to interactively view vital organs and anatomic structures within the human body. The company’s V3D technology software solutions include Viatronix V3D-Colon, V3D-Calcium Scoring, V3D-Cardiac, V3D-Vascular, and V3D-Explorer.

Related Links:
Viatronix